title: Statin therapy on glycaemic control in type 2 diabetes: a meta-analysis.
abstract: OBJECTIVE
  Randomised controlled trials (RCTs) indicate that statin therapy has cardiovascular benefit among patients with type 2 diabetes. Recently, statins were reported to increase risk of diabetes by 9%. The aim was to investigate by a meta-analysis whether statins deteriorate glycaemic control in type 2 diabetes.
  
  
  METHODS
  Medline, EMBASE and Cochrane Central Register of Controlled Trials from 1966 to 2012 were searched for RCTs of statins. Included were only trials with type 2 diabetes.
  
  
  METHODS
  The I(2) statistic was used to measure heterogeneity between trials and calculated mean differences for glycaemic parameters with random-effect meta-analysis.
  
  
  RESULTS
  26 eligible studies were identified with 3232 participants. Statin therapy had no remarkable influence on HbA1c (WMD 0.04%, 95% CI -0.08 to 0.16, I² = 45.7%, n = 3070), FPG (2.25 mg/dl, 95% CI -3.50 to 7.99, I² = 46%, n = 1176), BMI, fasting insulin or HOMA-IR. However, subgroup analysis showed significant, detrimental effect of atorvastatin on HbA1c, whereas simvastatin presented an ameliorative effect. Meta-regression presented that neither baseline age nor relative reduction in LDL-cholesterol concentrations accounted for residual heterogeneity.
  
  
  CONCLUSIONS
  Statin therapy showed non-significant effect on glycaemic control in type 2 diabetes. Statin therapy need not change among them with moderate or high cardiovascular risk or existing cardiovascular disease.
authors.affiliation: The Affiliated ZhongDa Hospital of Southeast University, Department of Endocrinology, No. 87 DingJiaQiao Road, Nanjing, 210009, PR China. zhouyi521520@163.com
authors.forename: Yi
authors.initials: Y
authors.lastname: Zhou
authors.forename: Yang
authors.initials: Y
authors.lastname: Yuan
authors.forename: Rong-Rong
authors.initials: RR
authors.lastname: Cai
authors.forename: Yan
authors.initials: Y
authors.lastname: Huang
authors.forename: Wen-Qing
authors.initials: WQ
authors.lastname: Xia
authors.forename: Yue
authors.initials: Y
authors.lastname: Yang
authors.forename: Pin
authors.initials: P
authors.lastname: Wang
authors.forename: Qiong
authors.initials: Q
authors.lastname: Wei
authors.forename: Shao-Hua
authors.initials: SH
authors.lastname: Wang
mesh_terms: D000368:Aged; D015992:Body Mass Index; D008078:Cholesterol, LDL / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D008875:Middle Aged
chemical_list: D008078:Cholesterol, LDL; D006442:Glycated Hemoglobin; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007004:Hypoglycemic Agents; D007328:Insulin; C517652:hemoglobin A1c protein, human